Meeting
2022 ASCO Annual Meeting
Sequential trans-arterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy (START-FIT) for locally advanced hepatocellular carcinoma: A single-arm, phase II trial.
Authors
Chi Leung Chiang
Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong Kong
Chi Leung Chiang , Wan Hang Keith Chiu , Wing Hang Vince Lau , Sik-Kwan Chan , Ann Shing Lee , Feng-Ming Spring Kong , Albert Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT 03817736
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4091)
DOI
10.1200/JCO.2022.40.16_suppl.4091
Abstract #
4091
Poster Bd #
78
Abstract Disclosures
Similar Posters
First Author: Chi Leung Chiang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
First Author: Guoliang Shao
Poster
2023 ASCO Annual Meeting
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.
First Author: Xiang Nong
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima